Related Experiment Video
Updated: Aug 7, 2026
07:40
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Customizing a commercial rule base for detecting drug-drug interactions
Ervina Resetar1, Richard M Reichley, Laura A Noirot
1Washington University School of Medicine, Department of Internal Medicine, St. Louis, MO, USA.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|June 17, 2006
Summary
We enhanced a drug safety system (PharmADE) to better detect dangerous drug combinations. Our methods improve rule sensitivity for critical drug-drug interaction detection, ensuring patient safety.
Area of Science:
- Pharmacovigilance
- Clinical Informatics
- Drug Safety
Background:
- Adverse drug events pose significant risks to patient safety.
- Existing drug-drug interaction (DDI) detection systems often lack optimal sensitivity.
- Commercial rule bases offer rapid deployment but may require refinement.
Purpose of the Study:
- To enhance the sensitivity of a commercial rule base for an adverse drug event system (PharmADE).
- To improve the detection of potentially dangerous drug combinations.
- To maintain the original rule base architecture for cost-effective maintenance.
Main Methods:
- Developed and implemented methods to enhance commercial DDI rules.
- Integrated enhanced rules into the PharmADE system.
- Preserved the original rule base architecture.
Main Results:
- The enhanced PharmADE system demonstrated improved sensitivity in detecting drug-drug interactions.
- Potentially dangerous drug combinations are identified with greater accuracy.
- The system maintains ease of maintenance and low cost.
Conclusions:
- Enhancing commercial DDI rules improves the effectiveness of pharmacovigilance systems.
- The modified PharmADE system offers a more sensitive safety net for identifying critical drug combinations.
- This approach balances improved safety with practical system maintenance.
Related Concept Videos
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:29Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:28Drug-Receptor Interaction: Antagonist
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
01:30Quantitative Aspects of Drug-Receptor Interaction
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower Kd...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...